Skeletal Maturation and Endocrine Health in Young Adults
NCT ID: NCT06509776
Last Updated: 2025-01-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
2000 participants
OBSERVATIONAL
2024-11-11
2031-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Genetic and Life Style Determinants of Bone Mass of Young Greek Males
NCT00449215
Role of Cardiometabolic Risk Factors in Childhood Bone Development
NCT02355717
Bone, Endocrine and Lifestyle Longitudinal Study
NCT02063074
Advancing Early Bone Health: New Frontiers for Osteoporosis Prevention
NCT06750523
Lifestyle Intervention to Improve Bone Quality
NCT03329963
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The overall aim of the project addresses whether the following sets of potential determinants are associated with young adult hormonal status, lipids, bone turnover markers, bone mineral density (BMD), fat mass and lean body mass at age 18 years: a) maternal risk factors during preconception and pregnancy; b) risk factors at birth; c) neonatal epigenetic signature; d) childhood risk factors.
Aim 1 - Epigenetics - Is peak bone mass and body size influenced by epigenetic profile for endocrine signals at birth? From the second trimester of pregnancy and until early adulthood, bone is gradually developed and shaped, with longitudinal growth dominating the later stages of fetal life, infancy, and childhood. This is followed by a period of rapid bone mineral accrual occurring up to and during puberty, with bone mass accretion ultimately reaching a plateau in young adult life. It is strongly suggested by prior research that epigenetic variation at birth can result from differences in maternal health, lifestyle, nutrition, smoking and medication usage and result in long-term changes in gene expression and metabolism.
As existing childhood cohorts either lack BMD information, suffer from significant cohort attrition, and low recruitment success, there is an opportunity to instead use national invitations to recruit directly into an efficient endocrine and bone outcomes study and use already archived biological material from early infancy and register data and obtain individual study subject consent.
Aim 2 - Endocrine status in young adulthood - Does maternal medication use and health issues prior to pregnancy or in pregnancy affect endocrine health in young adults? This question will be addressed using data from Danish national registers. While it is straightforward to link binary events data e.g., malformations or paediatric admissions (eg epilepsy, diabetes, failure to thrive) to registry capture of their maternal exposures, we will be obtaining detailed information about continuous outcomes including endocrine serum biochemistry (thyroid axis, GH axis, PTH-vitamin D-calcium axis, lipids, HbA1c), hair cortisol levels (a cumulative serum cortisol metric) as well as body composition and bone density metrics.
Aim 3 - DXA measured muscle, fat mass and lipid status in young adults - Do suboptimal conditions prior to pregnancy, during pregnancy, birth, and childhood, such as lifestyle, poor health and low socioeconomics adversely influence establishment of healthy body composition and lipid status in young adulthood? Detailed register-based information prior to pregnancy, about pregnancy, birth and childhood health will be used to identify areas open to prevention. Detailed information will be obtained via the Danish national health registers.
Statistical consideration - With a study population of 2,000, the power (given α=0.05) available to detect a 0.2 SD effect on a continuous outcome such as PBM for a risk factor with a population prevalence of 20% is 90%. With inclusion of 1,500 subjects, the corresponding study power is 90% for detection of an effect size of 0.24 SD or 80% for detection of an effect size of 0.2 SD. The study needs this resolving power to be able to address multiple contributing factors and for the inclusion of factors in the model that may have a population prevalence below 20%. Less common factors would, even if powerful drivers of skeletal health, be somewhat less useful in population impact even if successfully modified.
Biological material - All material for use in the current project will be stored in a research biobank during the current study during its term. Any remaining material is transferred to biobank for future research with the approval of the Danish Data Protection Agency. The purpose of the biobank is to ensure validation of the analysis methods used over time. The participants must give consent to the storage of their biological material in the biobank. It is completely optional if the participants want to donate their excess biological material to the biobank and if they do not want this, it does not affect their participation in the study. For new research, new consent must be obtained, but the Scientific Ethics Committee can grant exemption from the consent requirement.
All material will be stored in compliance with Danish legislation on data protection.
24 mL of blood will be drawn. All blood samples are encoded so that all samples are anonymized, and the key is under special protection and only with access for authorized personnel. All extra material will be kept in the biobank.
To ensure uniformity between neonatal and adolescent samples, DBS will be created from the freshly drawn whole blood. DBS are created by spotting 3x75µL onto a cotton filter paper of the same type used in 2006-2007. The cards are left overnight at ambient temperatures then transferred to -20C for long term storage. DNA is be extracted from two 3.2mm disks excised from the DBS card, then purified using magnetic silica beads. Finally, concentrations are measured using intercalating dyes.
All hair samples (minimum 20 mg per participant) will be encoded so that all samples are pseudonymised, and the key is under special protection and only with access for authorized personnel. All hair samples will be used in the analyses, and then discarded.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Population sample
Random subsample of all 17-18-year-old individuals in Denmark, i.e. live births from year 2006 and 2007.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Are 18 years old and alive at the time of the clinical examination
Exclusion Criteria
* No DBS samples available
* Lack of consent to use DBS samples or national health registries
* Emigration or disappearance
18 Years
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aarhus University Hospital
OTHER
Aalborg University Hospital
OTHER
University of Southern Denmark
OTHER
University Hospital Bispebjerg and Frederiksberg
OTHER
Zealand University Hospital
OTHER
Odense University Hospital
OTHER
Rigshospitalet, Denmark
OTHER
Statens Serum Institut
OTHER
Hvidovre University Hospital
OTHER
Holbaek Sygehus
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bo Abrahamsen, MD, PhD
Role: STUDY_CHAIR
OPEN, University of Southern Denmark, Odense and Department of Medicine 1, Holbæk Hospital, Holbæk
Katrine H Rubin, MHS, PhD
Role: PRINCIPAL_INVESTIGATOR
OPEN, Department of Clinical Research, University of Southern Denmark and Odense University Hospital
Bente Langdahl, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Department of Clinical Medicine and Department of Endocrinology and Diabetes, Aarhus University
Peter Vestergaard, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Faculty of Medicine, Aalborg University and Department of Endocrinology, Aalborg University Hospital
Berit L Heitmann, DMD, PhD
Role: PRINCIPAL_INVESTIGATOR
The Parker Institute, Frederiksberg Hospital, Frederiksberg
Mina N Händel, Msc, PhD
Role: PRINCIPAL_INVESTIGATOR
The Parker Institute, Frederiksberg Hospital, Frederiksberg
Charlotte L Tofteng, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Department of CIinical Medicine, Endocrinology, Zealand University Hospital, Køge
Pernille Bach-Mortensen, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Department of Endocrinology, Amager and Hvidovre Hospital, Hvidovre
Pernille Hermann, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Department of Endocrinology, Odense University Hospital, Odense
Niklas R Jørgensen, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Department of Clinical Biochemistry and Centre of Diagnostic Investigation,Rigshospitalet Copenhagen
Jonas Bybjerg-Grauholm, MSE
Role: PRINCIPAL_INVESTIGATOR
Danish Center for Neonatal Screening, Statens Serum Institut, Copenhagen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aalborg University Hospital, Department of Endocrinology
Aalborg, , Denmark
Aarhus University Hospital, Department of Endocrinology
Aarhus, , Denmark
Rigshospitalet, Department of Clinical Biochemistry and Endocrinology
Copenhagen, , Denmark
Bispebjerg and Frederiksberg Hospital, EEK, Parker Institute
Frederiksberg, , Denmark
Holbæk Hospital, Department of Medicine
Holbæk, , Denmark
Hvidovre Hospital, Department of Endocrinology
Hvidovre, , Denmark
Zealand University Hospital, Department of Medicine
Køge, , Denmark
Odense University Hospital, Department of Endocrinology
Odense, , Denmark
University of Southern Denmark, Department of Clinical Research
Odense, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Yu XH, Wei YY, Zeng P, Lei SF. Birth weight is positively associated with adult osteoporosis risk: observational and Mendelian randomization studies. J Bone Miner Res. 2021 Aug;36(8):1469-1480. doi: 10.1002/jbmr.4316. Epub 2021 Jun 9.
Curtis EM, Fuggle NR, Cooper C, Harvey NC. Epigenetic regulation of bone mass. Best Pract Res Clin Endocrinol Metab. 2022 Mar;36(2):101612. doi: 10.1016/j.beem.2021.101612. Epub 2022 Jan 4.
Krstic N, Bishop N, Curtis B, Cooper C, Harvey N, Lilycrop K, Murray R, Owen R, Reilly G, Skerry T, Borg S. Early life vitamin D depletion and mechanical loading determine methylation changes in the RUNX2, RXRA, and osterix promoters in mice. Genes Nutr. 2022 May 26;17(1):7. doi: 10.1186/s12263-022-00711-0.
Reppe S, Lien TG, Hsu YH, Gautvik VT, Olstad OK, Yu R, Bakke HG, Lyle R, Kringen MK, Glad IK, Gautvik KM. Distinct DNA methylation profiles in bone and blood of osteoporotic and healthy postmenopausal women. Epigenetics. 2017 Aug;12(8):674-687. doi: 10.1080/15592294.2017.1345832. Epub 2017 Jun 26.
Williams GR, Bassett JHD. Thyroid diseases and bone health. J Endocrinol Invest. 2018 Jan;41(1):99-109. doi: 10.1007/s40618-017-0753-4. Epub 2017 Aug 29.
Cardoso I, Specht IO, Thorsteinsdottir F, Thorbek MJ, Keller A, Stougaard M, Cohen AS, Handel MN, Kristensen LE, Heitmann BL. Vitamin D Concentrations at Birth and the Risk of Rheumatoid Arthritis in Early Adulthood: A Danish Population-Based Case-Cohort Study. Nutrients. 2022 Jan 20;14(3):447. doi: 10.3390/nu14030447.
Handel MN, Frederiksen P, Cohen A, Cooper C, Heitmann BL, Abrahamsen B. Neonatal vitamin D status from archived dried blood spots and future risk of fractures in childhood: results from the D-tect study, a population-based case-cohort study. Am J Clin Nutr. 2017 Jul;106(1):155-161. doi: 10.3945/ajcn.116.145599. Epub 2017 May 17.
Jensen CB, Lundqvist M, Sorensen TIA, Heitmann BL. Neonatal Vitamin D Levels in Relation to Risk of Overweight at 7 Years in the Danish D-Tect Case-Cohort Study. Obes Facts. 2017;10(3):273-283. doi: 10.1159/000471881. Epub 2017 Jun 10.
Keller A, Thorsteinsdottir F, Stougaard M, Cardoso I, Frederiksen P, Cohen AS, Vaag A, Jacobsen R, Heitmann BL. Vitamin D concentrations from neonatal dried blood spots and the risk of early-onset type 2 diabetes in the Danish D-tect case-cohort study. Diabetologia. 2021 Jul;64(7):1572-1582. doi: 10.1007/s00125-021-05450-2. Epub 2021 May 24.
Keller A, Frederiksen P, Handel MN, Jacobsen R, McGrath JJ, Cohen AS, Heitmann BL. Environmental and individual predictors of 25-hydroxyvitamin D concentrations in Denmark measured from neonatal dried blood spots: the D-tect study. Br J Nutr. 2019 Mar 14;121(5):567-575. doi: 10.1017/S0007114518003604. Epub 2019 Jan 30.
Keller A, Handel MN, Frederiksen P, Jacobsen R, Cohen AS, McGrath JJ, Heitmann BL. Concentration of 25-hydroxyvitamin D from neonatal dried blood spots and the relation to gestational age, birth weight and Ponderal Index: the D-tect study. Br J Nutr. 2018 Jun;119(12):1416-1423. doi: 10.1017/S0007114518000879. Epub 2018 Apr 25.
Thorsteinsdottir F, Cardoso I, Keller A, Stougaard M, Frederiksen P, Cohen AS, Maslova E, Jacobsen R, Backer V, Heitmann BL. Neonatal Vitamin D Status and Risk of Asthma in Childhood: Results from the D-Tect Study. Nutrients. 2020 Mar 21;12(3):842. doi: 10.3390/nu12030842.
Dugue PA, English DR, MacInnis RJ, Jung CH, Bassett JK, FitzGerald LM, Wong EM, Joo JE, Hopper JL, Southey MC, Giles GG, Milne RL. Reliability of DNA methylation measures from dried blood spots and mononuclear cells using the HumanMethylation450k BeadArray. Sci Rep. 2016 Jul 26;6:30317. doi: 10.1038/srep30317.
Staunstrup NH, Starnawska A, Nyegaard M, Christiansen L, Nielsen AL, Borglum A, Mors O. Genome-wide DNA methylation profiling with MeDIP-seq using archived dried blood spots. Clin Epigenetics. 2016 Jul 26;8:81. doi: 10.1186/s13148-016-0242-1. eCollection 2016.
Ghantous A, Saffery R, Cros MP, Ponsonby AL, Hirschfeld S, Kasten C, Dwyer T, Herceg Z, Hernandez-Vargas H. Optimized DNA extraction from neonatal dried blood spots: application in methylome profiling. BMC Biotechnol. 2014 Jul 1;14:60. doi: 10.1186/1472-6750-14-60.
Weaver CM, Gordon CM, Janz KF, Kalkwarf HJ, Lappe JM, Lewis R, O'Karma M, Wallace TC, Zemel BS. The National Osteoporosis Foundation's position statement on peak bone mass development and lifestyle factors: a systematic review and implementation recommendations. Osteoporos Int. 2016 Apr;27(4):1281-1386. doi: 10.1007/s00198-015-3440-3. Epub 2016 Feb 8.
Hannon E, Schendel D, Ladd-Acosta C, Grove J, Hansen CS, Hougaard DM, Bresnahan M, Mors O, Hollegaard MV, Baekvad-Hansen M, Hornig M, Mortensen PB, Borglum AD, Werge T, Pedersen MG, Nordentoft M; iPSYCH-Broad ASD Group; Buxbaum JD, Daniele Fallin M, Bybjerg-Grauholm J, Reichenberg A, Mill J. Variable DNA methylation in neonates mediates the association between prenatal smoking and birth weight. Philos Trans R Soc Lond B Biol Sci. 2019 Apr 15;374(1770):20180120. doi: 10.1098/rstb.2018.0120.
Gicquel C, El-Osta A, Le Bouc Y. Epigenetic regulation and fetal programming. Best Pract Res Clin Endocrinol Metab. 2008 Feb;22(1):1-16. doi: 10.1016/j.beem.2007.07.009.
Jensen KH, Riis KR, Abrahamsen B, Handel MN. Nutrients, Diet, and Other Factors in Prenatal Life and Bone Health in Young Adults: A Systematic Review of Longitudinal Studies. Nutrients. 2020 Sep 19;12(9):2866. doi: 10.3390/nu12092866.
Harvey N, Dennison E, Cooper C. Osteoporosis: a lifecourse approach. J Bone Miner Res. 2014 Sep;29(9):1917-25. doi: 10.1002/jbmr.2286.
Gluckman PD, Hanson MA, Cooper C, Thornburg KL. Effect of in utero and early-life conditions on adult health and disease. N Engl J Med. 2008 Jul 3;359(1):61-73. doi: 10.1056/NEJMra0708473. No abstract available.
Lillycrop K, Murray R, Cheong C, Teh AL, Clarke-Harris R, Barton S, Costello P, Garratt E, Cook E, Titcombe P, Shunmuganathan B, Liew SJ, Chua YC, Lin X, Wu Y, Burdge GC, Cooper C, Inskip HM, Karnani N, Hopkins JC, Childs CE, Chavez CP, Calder PC, Yap F, Lee YS, Chong YS, Melton PE, Beilin L, Huang RC, Gluckman PD, Harvey N, Hanson MA, Holbrook JD; EpiGen Consortium; Godfrey KM. ANRIL Promoter DNA Methylation: A Perinatal Marker for Later Adiposity. EBioMedicine. 2017 May;19:60-72. doi: 10.1016/j.ebiom.2017.03.037. Epub 2017 Apr 26.
Godfrey KM, Costello PM, Lillycrop KA. The developmental environment, epigenetic biomarkers and long-term health. J Dev Orig Health Dis. 2015 Oct;6(5):399-406. doi: 10.1017/S204017441500121X. Epub 2015 May 28.
Block T, El-Osta A. Epigenetic programming, early life nutrition and the risk of metabolic disease. Atherosclerosis. 2017 Nov;266:31-40. doi: 10.1016/j.atherosclerosis.2017.09.003. Epub 2017 Sep 5.
Godfrey KM, Costello PM, Lillycrop KA. Development, Epigenetics and Metabolic Programming. Nestle Nutr Inst Workshop Ser. 2016;85:71-80. doi: 10.1159/000439488. Epub 2016 Apr 18.
Godfrey KM, Sheppard A, Gluckman PD, Lillycrop KA, Burdge GC, McLean C, Rodford J, Slater-Jefferies JL, Garratt E, Crozier SR, Emerald BS, Gale CR, Inskip HM, Cooper C, Hanson MA. Epigenetic gene promoter methylation at birth is associated with child's later adiposity. Diabetes. 2011 May;60(5):1528-34. doi: 10.2337/db10-0979. Epub 2011 Apr 6.
Godfrey KM, Lillycrop KA, Burdge GC, Gluckman PD, Hanson MA. Epigenetic mechanisms and the mismatch concept of the developmental origins of health and disease. Pediatr Res. 2007 May;61(5 Pt 2):5R-10R. doi: 10.1203/pdr.0b013e318045bedb.
Hollegaard MV, Grauholm J, Norgaard-Pedersen B, Hougaard DM. DNA methylome profiling using neonatal dried blood spot samples: a proof-of-principle study. Mol Genet Metab. 2013 Apr;108(4):225-31. doi: 10.1016/j.ymgme.2013.01.016. Epub 2013 Feb 1.
Handel MN, Jorgensen NR, Bybjerg-Grauholm J, Jansen RB, Eiken P, Tofteng CL, Hermann AP, Bach-Mortensen P, Heitmann BL, Rubin KH, Langdahl BL, Vestergaard P, Abrahamsen B. Early life determinants of skeletal maturation, body composition and endocrine health in young adults (EPIPEAK): protocol for a nationwide birth cohort study. BMJ Open. 2025 Oct 23;15(10):e101632. doi: 10.1136/bmjopen-2025-101632.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NNF22OC0080437
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
21-B-0436
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
S-20230105
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.